Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD20 + status confers therapeutic sensitivity to Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine in patients with Non-Hodgkin Lymphoma.
The European Medicines Agency (EMA) has authorized rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma.
This statement is based on a regulatory approval from the European Medicines Agency:
MabThera is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine,prednisolone) chemotherapy.